Roche expands into cell therapy with $1.5B Poseida purchase
Photo shows the logo of Swiss pharmaceutical giant Roche in Basel, Switzerland. (AFP Photo)
Swiss medicine giant Roche announced the acquisition of cell therapy maker firm Poseida Therapeutics on Tuesday, for a total transaction value of $1.5 billion.
“The acquisition will facilitate a range of potentially ‘first and best-in-class therapies’ across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies,” Roche stated in a press release.
The transaction is expected to be completed in the first quarter of 2025. The acquisition will be done for $9 per share, and shareholders will also receive a non-tradeable contingent value right for around $4 per share, representing a total deal value of some $1.5 billion.
Poseida is a public clinical-stage biopharmaceutical firm in donor-derived CAR-T cell therapies, based in California, the U.S.
Poseida’s research and development portfolio includes preclinical and clinical-stage off-the-shelf chimeric antigen receptor T (CAR-T) therapies across several therapeutic areas, including hematological malignancies, solid tumors and autoimmune disease, as well as manufacturing capabilities and technology platforms.
